HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 321 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $294,631,787 | +9.5% | 7,712,874 | +3.4% | 0.50% | +15.5% |
| Q2 2023 | $269,064,562 | +0.8% | 7,459,511 | +6.7% | 0.43% | -1.4% |
| Q1 2023 | $267,031,698 | -34.3% | 6,992,189 | -2.1% | 0.44% | -38.9% |
| Q4 2022 | $406,320,226 | +67.7% | 7,140,953 | +16.5% | 0.72% | +68.5% |
| Q3 2022 | $242,297,000 | -13.5% | 6,127,892 | -3.7% | 0.43% | -9.9% |
| Q2 2022 | $280,076,000 | -24.4% | 6,365,361 | -31.4% | 0.47% | -3.3% |
| Q1 2022 | $370,313,000 | -3.1% | 9,285,686 | -2.3% | 0.49% | +7.9% |
| Q4 2021 | $382,227,000 | -6.8% | 9,505,768 | -5.7% | 0.45% | -9.4% |
| Q3 2021 | $409,917,000 | -11.4% | 10,076,613 | -1.1% | 0.50% | -9.4% |
| Q2 2021 | $462,714,000 | +6.0% | 10,189,688 | -2.7% | 0.55% | 0.0% |
| Q1 2021 | $436,418,000 | -0.6% | 10,468,159 | +1.8% | 0.55% | +3.2% |
| Q4 2020 | $439,235,000 | +7.7% | 10,284,136 | -33.7% | 0.54% | -7.1% |
| Q3 2020 | $407,811,000 | -9.5% | 15,517,924 | -7.7% | 0.58% | -20.2% |
| Q2 2020 | $450,607,000 | +73.6% | 16,807,413 | +16.5% | 0.72% | +29.9% |
| Q1 2020 | $259,596,000 | +178.3% | 14,430,037 | +174.3% | 0.56% | +241.1% |
| Q4 2019 | $93,269,000 | +90.3% | 5,260,496 | +66.4% | 0.16% | +75.3% |
| Q3 2019 | $49,023,000 | +42.7% | 3,160,743 | +58.1% | 0.09% | +47.6% |
| Q2 2019 | $34,349,000 | +3.8% | 1,999,363 | -2.7% | 0.06% | -3.1% |
| Q1 2019 | $33,092,000 | +10.9% | 2,055,396 | +0.8% | 0.06% | -3.0% |
| Q4 2018 | $29,834,000 | -24.0% | 2,039,215 | -5.7% | 0.07% | -10.7% |
| Q3 2018 | $39,281,000 | +36.2% | 2,161,872 | +26.5% | 0.08% | +29.3% |
| Q2 2018 | $28,831,000 | -13.3% | 1,709,020 | +0.7% | 0.06% | -14.7% |
| Q1 2018 | $33,259,000 | -0.6% | 1,697,760 | +2.8% | 0.07% | +7.9% |
| Q4 2017 | $33,446,000 | +34.1% | 1,650,853 | +15.0% | 0.06% | +37.0% |
| Q3 2017 | $24,941,000 | +94.9% | 1,435,886 | +43.8% | 0.05% | +91.7% |
| Q2 2017 | $12,800,000 | -4.6% | 998,407 | -3.6% | 0.02% | -7.7% |
| Q1 2017 | $13,424,000 | – | 1,035,837 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |